Stock Scorecard
Stock Summary for Regulus Therapeutics Inc (RGLS) - $1.40 as of 11/20/2024 8:38:57 PM EST
Total Score
9 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RGLS
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RGLS
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RGLS
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for RGLS
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for RGLS (23 out of 90)
| Stock Price Rating (Max of 10) | 2 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 2 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
Latest News for for RGLS
Financial Details for RGLS
Company Overview |
|
|---|---|
| Ticker | RGLS |
| Company Name | Regulus Therapeutics Inc |
| Country | USA |
| Description | Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of drugs that target microRNAs to treat a variety of diseases in the United States. The company is headquartered in San Diego, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 9/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 1.40 |
| Price 4 Years Ago | 13.50 |
| Last Day Price Updated | 11/20/2024 8:38:57 PM EST |
| Last Day Volume | 151,065 |
| Average Daily Volume | 401,184 |
| 52-Week High | 3.00 |
| 52-Week Low | 1.08 |
| Last Price to 52 Week Low | 29.63% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 22.60 |
| Sector PE | 40.32 |
| 5-Year Average PE | -1.46 |
| Free Cash Flow Ratio | 1.05 |
| Industry Free Cash Flow Ratio | 12.03 |
| Sector Free Cash Flow Ratio | 27.97 |
| Current Ratio Most Recent Quarter | 14.14 |
| Total Cash Per Share | 1.33 |
| Book Value Per Share Most Recent Quarter | 1.32 |
| Price to Book Ratio | 1.08 |
| Industry Price to Book Ratio | 5.31 |
| Sector Price to Book Ratio | 20.88 |
| Price to Sales Ratio Twelve Trailing Months | 7.43 |
| Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
| Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 65,500,000 |
| Market Capitalization | 91,700,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | -6.05% |
| Reported EPS 12 Trailing Months | -1.02 |
| Reported EPS Past Year | -0.67 |
| Reported EPS Prior Year | -1.59 |
| Net Income Twelve Trailing Months | -41,628,000 |
| Net Income Past Year | -30,037,000 |
| Net Income Prior Year | -28,323,000 |
| Quarterly Revenue Growth YOY | 27,678.00% |
| 5-Year Revenue Growth | -38.92% |
| Operating Margin Twelve Trailing Months | 0.00 |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 87,300,000 |
| Total Cash Past Year | 23,800,000 |
| Total Cash Prior Year | 39,200,000 |
| Net Cash Position Most Recent Quarter | 84,506,000 |
| Net Cash Position Past Year | 19,127,000 |
| Long Term Debt Past Year | 4,673,000 |
| Long Term Debt Prior Year | 4,673,000 |
| Total Debt Most Recent Quarter | 2,794,000 |
| Equity to Debt Ratio Past Year | 0.82 |
| Equity to Debt Ratio Most Recent Quarter | 0.97 |
| Total Stockholder Equity Past Year | 21,187,000 |
| Total Stockholder Equity Prior Year | 33,291,000 |
| Total Stockholder Equity Most Recent Quarter | 86,805,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -36,364,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.56 |
| Free Cash Flow Past Year | -27,381,000 |
| Free Cash Flow Prior Year | -25,887,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.02 |
| MACD Signal | -0.02 |
| 20-Day Bollinger Lower Band | 1.38 |
| 20-Day Bollinger Middle Band | 1.60 |
| 20-Day Bollinger Upper Band | 1.82 |
| Beta | 1.63 |
| RSI | 48.86 |
| 50-Day SMA | 1.77 |
| 150-Day SMA | 1.75 |
| 200-Day SMA | 3.66 |
System |
|
| Modified | 11/19/2024 11:30:56 AM EST |